NTI drugs and Full Replicate [Design Issues]

posted by Pharma_88 – India, 2020-03-10 07:39 (1946 d 05:13 ago) – Posting: # 21232
Views: 7,838

Dear All,

Greetings!!

For NTI drugs, USFDA suggested to perform full replicate design despite of having low to moderate ISCV. My question is that is there any specific guidance is available from FDA behind this rationale? Further, can we perform crossover studies for NTI by taking extra safety measurement in to the study? Further, what is the BE limit for such drugs? 2003 guidelines having information on NTI however draft 2014 doesn't have any info for NTI.

For Example, FDA suggested to perform BE for Sodium valporic acid as full replicate despite of having low ISCV. However, available PAR reports having crossover design.

Thanks,
Pharma_88

Regards,
Pharma_88

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,697 registered users;
97 visitors (0 registered, 97 guests [including 32 identified bots]).
Forum time: 13:53 CEST (Europe/Vienna)

Anyone who conducts an argument by appealing to authority
is not using his intelligence;
he is just using his memory.    Leonardo da Vinci

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5